- 1 Serum fibrinogen level and fibrinogen administration in
- 2 patients with traumatic brain injury: a systematic review
- 3 and meta-analysis protocol
- 5 Joanne Igoli^{1,2,#}, Jeremiah Oluwatomi Itodo Daniel^{2,#}, Halleluyah Oludele², Adedoyin Esther
- 6 Alao², Idemudia Stephen Ogedegbe², Adewale Olaniyan², Michael Adeshola Adebayo²,
- 7 Damilola Matthew², Temidayo Elizabeth Oyepitan², Daniel Brabi², Olatomiwa Olukoya^{2,3},
- 8 Temidayo Osunronbi^{2,4}
- 10 1. Deanery of Clinical Sciences, The University of Edinburgh, Edinburgh, United
- 11 Kingdom

9

17

19

- 12 2. Neurosurgery Department, Surgery Interest Group of Africa, Lagos, Nigeria
- 13 3. National Hospital for Neurology and Neurosurgery, London, United Kingdom
- 4. Department of Neurosurgery, Salford Royal NHS Foundation Trust, Manchester,
- 15 United Kingdom
- # Joint-first authors: contributed equally.
- 18 Please address all correspondence to:
- 20 Dr Joanne Igoli

21 Deanery of Clinical Sciences, The University of Edinburgh, Edinburgh, United Kingdom. 22 EH16 4SB 23 Email: s1408071@sms.ed.ac.uk ABSTRACT 24 25 **Introduction:** Traumatic Brain Injury (TBI) is a leading cause of disability and death globally. It has a significant economic burden. Coagulopathy has been identified as one of 26 the key factors contributing to the poor outcomes observed in TBI patients, and it has been 27 theorised that the management of coagulopathy will improve patient outcomes. 28 Low serum fibrinogen levels denote a coagulopathic state, and the therapeutic 29 administration of fibrinogen has been proposed to correct this state. However, there is no 30 consensus on its efficacy in patients with TBI. 31 32 This systematic review and meta-analysis seeks to ascertain the prognostic value of 33 serum fibrinogen levels in patients with TBI and assess the effect of fibrinogen administration on these patients. 34 35 Methods: Using the Preferred Reporting Items for Systematic Review and Meta-Analysis 36 Protocols (PRISMA-P) guidelines, we will perform a comprehensive search of Scopus, 37 Medline, Embase and Cochrane Library to retrieve all original articles that investigate the 38 39 prognostic value of fibrinogen levels and/or the effect of fibrinogen administration in TBI

patients. Primary outcomes include functional outcome and mortality assessments such

40

41 as the Glasgow Outcome Score and modified Rankin Score. Secondary outcomes include progressive intracranial haemorrhage/contusion and need for surgical intervention. Data 42 collected will encompass participant demographics, measured fibrinogen levels, dose of 43 44 fibrinogen administered and specified outcome measures. 45 <u>Conclusion</u>: Findings from this study on if fibrinogen level has prognostic value and if 46 fibringen administration improves patient outcomes, will help inform future TBI 47 management and shared decision-making. Thus, TBI patient outcomes can be optimised 48 accordingly. 49 50 PROSPERO Registration Number: CRD42024556497. Available from: 51 52 https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024556497 53 <u>Keywords:</u> Traumatic Brain Injury; Fibrinogen; Coagulopathy; Glasgow Outcome Scale; 54 modified Rankin Score 55 56 Short Title: Fibrinogen in TBI systematic review protocol. 57

Introduction

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

Traumatic Brain Injury (TBI) is a leading cause of disability and death, with an incidence of approximately 69 million people per year globally[1] and a prevalence of approximately 75 million [1,2]. The estimated global economic cost of TBI is \$400 billion [3]. Approximately half of TBI patients seen in hospitals fail to regain pre-TBI baseline health six months after the injury [2]. Seguelae of TBI range from transient loss of consciousness and confusion to seizures, persistent cognitive decline, coma, and death [4-6]. Coagulopathy in TBI influences the development of intracranial haemorrhage (ICH), leading to poor patient outcomes, including a higher incidence of organ failure, poor neurological function recovery, significant disability, and death [7-9]. Fibrinogen plays a vital role in the clotting cascade of stabilising blood clots. A low fibrinogen level is a marker of coagulopathy. Serum fibrinogen level has been shown to decrease significantly hours after trauma and reaches severely low levels in uncontrolled post-traumatic bleed[10]. Furthermore, adverse associations of low fibringen levels in patients with TBI have been shown, such as loss of independence due to severe disability, vegetative state, and death [9,11,12]. It has been postulated that low fibrinogen levels can be used to prognosticate patients with TBI, and therapeutic administration of fibrinogen could improve coagulopathy in these patients, improving their outcomes. This systematic review aims first to assess the evidence on the prognostic value of fibrinogen in TBI, which would benefit risk-benefit shared decision-making involving

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

healthcare providers, patients, and their families. Secondly, the authors aim to evaluate the evidence on the benefits, if any, of fibrinogen administration in patients with TBI, which, if demonstrated, would transform and broaden treatment options in this group of patients. Materials and Methods Research Questions Question 1: Is there a prognostic value of fibrinogen level in patients with traumatic brain injury? Population: Patients with traumatic brain injury (TBI) Intervention: Serum fibrinogen level Control: N/A Outcomes: Glasgow outcome score; need for surgical intervention; mortality; functional outcomes; progressive intracranial haemorrhage/contusion; other. Question 2: What is the effect of fibrinogen administration on outcomes in patients with traumatic brain injury?

102 103 Population: Patients with traumatic brain injury (TBI) 104 105 Intervention: Fibrinogen administered 106 107 Control: Fibrinogen not administered 108 109 Outcomes: Glasgow outcome score; need for surgical intervention; mortality; 110 functional outcomes; progressive intracranial haemorrhage/contusion; other. 111 Data Collection 112 Literature Search Strategy 113 114 We searched the abstracts and titles of articles in Medline, SCOPUS, Cochrane, and EMBASE databases from inception to June 01, 2024, using the following search strategy: 115 116 117 #1 head OR craniu* OR crania* OR cerebra* OR cerebru* OR brain* OR forebrain* OR skull* OR 118 hemispher* OR intracran* OR intracerebral 119 #2 injur* OR trauma* OR damag* OR wound* OR fracture* OR contusion* OR haematoma OR 120 hematoma OR haemorrhage OR hemorrhage 121 #3 Factor I OR Fibrinogen OR Fibrin OR Fibrinogen concentrate OR Hypofibrinogenemia OR 122 Hypofibrinogenaemia OR Fibrin degradation product OR Coagulopathy OR Clot* OR Haematolog* 123 OR Hematolog* OR Cryoprecipitate OR Riastap OR Fresh Frozen Plasma 124 #4 #1 AND #2 AND #3

The initial results of the search strategy are shown in Table 1.

Table 1: Search Strategy Table

125

126

127

128

Database	Count
Scopus	38,066
Medline	8256
Embase	15139
Cochrane	2543

129 Eligibility Criteria

130 Inclusion Criteria

- 131 We will include full-text original articles that investigate the prognostic value of serum fibrinogen
- 132 level and/or investigate the effects of fibrinogen administration on outcomes in TBI patients.

133 Exclusion Criteria

- Review articles, expert opinions, editorials, letters, conference abstracts, case reports, case series,
- non-English language papers, paediatric-focussed studies and non-human studies will be excluded.
- 136 Studies in which fibringen was used solely as a marker of disease severity and/or solely for
- diagnostic reasons will also be excluded.

138 139 Data Extraction 140 141 Zotero (Corporation for Digital Scholarship, Virginia, USA) will be used to exclude literature search 142 duplicates. Using Rayyan (Rayyan, Cambridge, Massachusetts, USA), titles/abstracts will be 143 independently screened by two reviewers for inclusion. Eligible full-text articles will be screened 144 further, and subsequent data extracted using the same data extraction proforma on Google Sheets 145 (Google LLC, Mountain View, California, USA). A third reviewer will adjudicate any conflicts in 146 title/abstract screening, full-text screening, and data extraction. The process will be illustrated using 147 a Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) [13] flow 148 diagram. 149 Data to be extracted: 150 151 Title 152 Author 153 Publication year 154 Study design Country of study: Based on where the study took place. The first author's country will be 155 used when the study location is not specified. 156 Cause of TBI, if included, such as blunt trauma, penetrating trauma, other 157 158 Neurosurgical procedures carried out such as decompressive craniectomy or craniotomy 159 for extradural clot evacuation.

160	• Exclusion criteria
161	Number of patients
162	• Age (mean ± SD/median (IQR))
163	Sex (male/female proportion)
164	Day serum fibrinogen blood sample was obtained
165	Average fibrinogen level
166	• Level of serum fibrinogen that triggered fibrinogen administration (if serum fibrinogen was
167	checked pre-fibrinogen administration)
168	• Day fibrinogen was administered: Preoperative or postoperative. If postoperative, the day(s)
169	fibrinogen was administered will be extracted
170	Dose(s) of fibrinogen administered
171	Number of times fibrinogen was administered and the triggers for subsequent
172	administration
173	Outcome measure: The nature of the outcome measure to be identified is uncertain.
174	Therefore, there will be no prior criteria. It is anticipated that outcomes such as the
175	following will be identified and used as inclusion criteria:
176	o Glasgow Outcome Score (GOS)/Glasgow Outcome Score Extended (GOSE)
177	Modified Rankin Score
178	o Mortality
179	Quality of life
180	Progressive intracranial haemorrhage/contusion
181	o Other
182	For each outcome measure, the following will be extracted:
183	o Length of stay (LOS)
184	Number of patients with event/number without event

185 Length of follow-up Number of patients lost to follow-up 186 187 o Low serum fibrinogen threshold 188 The method used for threshold selection 189 Area under the curve (AUC) 190 Sensitivity 191 Specificity 192 Event ratio with 95% confidence interval (CI) 193 Conclusion (on the association between fibrinogen level and outcome measure; on 194 association between fibrinogen administration and outcome measure). 195 Multivariate data will be preferred if both multivariate and univariate data are provided. 196 However, univariate data will be used instead in the absence of multivariate data. For AUC, 197 solely univariate data will be used.

Data Analysis

198

199

200

201

202

203

204

205

206

207

The direction of effect for the association between serum fibrinogen level or fibrinogen administration and patient outcomes will be categorised as significantly positive, significantly negative, or not statistically significant from articles where the event ratio is reported. Where the area under the curve (AUC) is reported, the effect direction will be grouped as failed (AUC = 0.5 to 0.6), poor (AUC = 0.6 to 0.7), acceptable (AUC = 0.7 to 0.8), good (AUC = 0.8 to 0.9) and excellent (AUC > 0.9) [14]. Dose and response analyses will be done [15], where possible, to evaluate the most effective dose of fibrinogen administration. Side effect frequency and severity will be reported.

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

Where possible, if ≥5 appropriate articles, meta-analysis will be performed using Review Manager (RevMan) (Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration) as follows: each outcome measure will have a pooled extracted odds ratio (OR)/hazard ratio (HR) with the corresponding 95% confidence interval (CI). The generic inverse-variance method will be used to assess the association between fibrinogen level/fibrinogen administration and the dichotomous outcome measure. The Cochrane O-statistic and I² statistic tests will be used to assess heterogeneity among included studies. Study heterogeneity will be addressed using a randomeffects model. Subgroup analyses will be carried out for studies that explicitly state that their study participants had isolated head injuries. Subgroup analyses will be conducted through sensitivity analysis, where the primary analysis is repeated after excluding studies with a high risk of bias. The risk of bias (RoB) in the eligible full-text articles will be assessed by two independent reviewers, with a third reviewer adjudicating any discrepancies. The RoB in studies investigating the prognostic utility of serum fibrinogen level will be assessed using the Quality in prognosis studies (QUIPs) tool [16]. The categories of high, moderate, and low risk of bias will used based on the criteria developed by Grooten et al [16]: green (low risk of bias) for studies where all six QUIPs domains are assessed as low risk of bias (RoB) or not more than one domain is assessed as moderate risk of bias; red (high RoB) for studies where ≥ 1 is assessed as high RoB, or ≥ 3 domains are assessed as moderate RoB; yellow (moderate RoB) for all other articles in between. The same criteria will be used to assess the risk of bias rating for individual domains. For the studies investigating the efficacy of fibrinogen administration, the Cochrane Risk of Bias tool will be used for Randomised control trials (RCTs) [17], and the ROBINS-I tool for nonrandomised studies to determine the RoB [18]. The RoB of RCTs will be rated as high, low, or

unclear. A green circle with a '+' symbol within will be used for low RoB, a red circle with a '-' symbol within for high RoB, and a yellow circle with a '?' symbol within for unclear RoB. For the ROBINS-I tool the categories used will be low risk, moderate risk, serious risk, and critical risk of bias [18]. Publication bias will be assessed through funnel plots and Egger's regression test, contingent on having an adequate number of studies. The GRADE framework will be used to assess the certainty of the evidence of the synthesis findings for each outcome measure in cases of fibrinogen administration and prognostication [19,20]. Two independent reviewers will conduct the GRADE assessments, with a third reviewer adjudicating any discrepancies.

If meta-analysis is not possible, the Synthesis without meta-analysis (SWiM) in systematic review reporting guidelines will be used to report narrative and qualitative data [21].

Study Limitations

Due to the nature of this systematic review's exclusion criteria, potentially valuable information in these excluded studies may be missed. Potentially valuable information from the data in studies that fail to report the events ratio or area under curve (AUC) whilst assessing the prognostic value of fibrinogen will also be missed as the data in these studies will not be included in our data analysis.

Conclusions

Given the prevalence of TBI and the worldwide economic burden, optimising the care of TBI patients is pertinent. If fibrinogen has a prognostic value, it would help healthcare teams practise realistic medicine in accordingly adjusting the goals of care delivered to these patients based on their prognosis. If administering fibrinogen does indeed improve patient outcomes, then this would be an important treatment option for healthcare teams to consider incorporating for TBI patients, especially if fibrinogen administration is protective against haemorrhagic transformation of contusions for example.

Therefore, if we find that serum fibrinogen level has prognostic value and that administering fibrinogen improves outcome, this could be important in shared-decision making and in ensuring that patients have improved outcomes.

Declarations 264 Ethics and Study Dissemination 265 No ethical approval is required for this systematic review of already published data. The findings of 266 267 this paper will be submitted for publishing in a peer-reviewed journal. Authors' contributions 268 269 Joanne Igoli, Jeremiah Oluwatomi Itodo Daniel, and Temidayo Osunronbi contributed to the 270 conception and design of the study. Joanne Igoli wrote the initial draft of the manuscript and is 271 guarantor of the study. All authors contributed to subsequent versions of the manuscript. All 272 authors read and approved the final manuscript. Acknowledgments 273 We would like to express our gratitude to the Surgery Interest Group of Africa for their support. 274 We would like to thank Idemudia Stephen Ogedegbe for his work on the protocol manuscript, after 275 276 which his contribution ended. 277

278 References

- Dewan MC, Rattani A, Gupta S, Baticulon RE, Hung YC, Punchak M, et al. Estimating the global incidence of traumatic brain injury. J Neurosurg. 2018 Apr;130(4):1080-97.
- Maas AIR, Menon DK, Manley GT, Abrams M, Åkerlund C, Andelic N, et al. Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurol. 2022
 Nov;21(11):1004–60.
- Howe EI, Andelic N, Fure SCR, Røe C, Søberg HL, Hellstrøm T, et al. Cost-effectiveness
 analysis of combined cognitive and vocational rehabilitation in patients with mild-to-moderate
 TBI: results from a randomized controlled trial. BMC Health Serv Res. 2022 Dec;22(1):185.
- Haarbauer-Krupa J, Pugh MJ, Prager EM, Harmon N, Wolfe J, Yaffe K. Epidemiology of Chronic Effects of Traumatic Brain Injury. J Neurotrauma. 2021 Dec 1;38(23):3235–47.
- 289 5. Capizzi A, Woo J, Verduzco-Gutierrez M. Traumatic Brain Injury. Med Clin North Am. 2020
 290 Mar;104(2):213-38.
- Theadom A, Parag V, Dowell T, McPherson K, Starkey N, Barker-Collo S, et al. Persistent
 problems 1 year after mild traumatic brain injury: a longitudinal population study in New
 Zealand. Br J Gen Pract. 2016 Jan;66(642):e16–23.
- Carrick MM, Tyroch AH, Youens CA, Handley T. Subsequent Development of
 Thrombocytopenia and Coagulopathy in Moderate and Severe Head Injury: Support for Serial
 Laboratory Examination: J Trauma Inj Infect Crit Care. 2005 Apr;58(4):725–30.
- Wafaisade A, Lefering R, Tjardes T, Wutzler S, Simanski C, Paffrath T, et al. Acute
 Coagulopathy in Isolated Blunt Traumatic Brain Injury. Neurocrit Care. 2010 Apr;12(2):211–9.
- Juratli TA, Zang B, Litz RJ, Sitoci KH, Aschenbrenner U, Gottschlich B, et al. Early Hemorrhagic
 Progression of Traumatic Brain Contusions: Frequency, Correlation with Coagulation
 Disorders, and Patient Outcome: A Prospective Study. J Neurotrauma. 2014 Sep;31(17):1521–7.
- 303 10. Raza I, Davenport R, Rourke C, Platton S, Manson J, Spoors C, et al. The incidence and
 304 magnitude of fibrinolytic activation in trauma patients. J Thromb Haemost. 2013
 305 Feb;11(2):307-14.
- 306 11. Sikka M, Sodhi R, Kotru M, Singh G. Markers of fibrinolysis in Indian patients with isolated head trauma. Asian J Neurosurg. 2019 Mar;14(01):118–21.
- Lv K, Yuan Q, Fu P, Wu G, Wu X, Du Z, et al. Impact of fibrinogen level on the prognosis of patients with traumatic brain injury: a single-center analysis of 2570 patients. World J Emerg
 Surg. 2020 Dec;15(1):54.
- 311 13. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA
 312 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021 Mar
 313 29;n71.
- 314 14. Mandrekar JN. Receiver Operating Characteristic Curve in Diagnostic Test Assessment. J
 315 Thorac Oncol. 2010 Sep;5(9):1315-6.
- 316 15. Shim SR, Lee J. Dose-response meta-analysis: application and practice using the R software. 317 Epidemiol Health. 2019 Mar 28:41:e2019006.
- 318 16. Grooten WJA, Tseli E, Äng BO, Boersma K, Stålnacke BM, Gerdle B, et al. Elaborating on the assessment of the risk of bias in prognostic studies in pain rehabilitation using QUIPS—
 320 aspects of interrater agreement. Diagn Progn Res. 2019 Dec;3(1):5.
- 321 17. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane
 322 Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct
 323 18;343(oct18 2):d5928-d5928.

- 324 18. Sterne J, Hernán M, McAleenan A, Reeves B, Higgins J. Chapter 25: Assessing risk of bias in a non-randomized study. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. Cochrane Handbook for Systematic Reviews of Interventions [Internet]. Version 6.4.
 327 2023 [cited 2024 May 1]. Available from: https://training.cochrane.org/handbook/current/chapter-25
- Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al. Judging
 the quality of evidence in reviews of prognostic factor research: adapting the GRADE
 framework. Syst Rev. 2013 Dec;2(1):71.
- 332 20. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1.
 333 Introduction—GRADE evidence profiles and summary of findings tables. J Clin Epidemiol.
 334 2011 Apr;64(4):383–94.
- Campbell M, McKenzie JE, Sowden A, Katikireddi SV, Brennan SE, Ellis S, et al.
 Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ.
 2020 Jan 16;l6890.